Prelude Therapeutics (PRLD) Stock Price, News & Analysis

Company Overview

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Key Stats

• Today's Range: $0.96 to $0.96
• 50-Day Range: $0.94 to $4.83
• 52-Week Range: $0.93 to $6.80
• Volume: 200 shs
• Average Volume: 162,775 shs
• Market Capitalization: $52.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.75
• Consensus Rating: Hold

Prelude Therapeutics Stock Analysis - MarketRank™

Prelude Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 536th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Prelude Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, no hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Prelude Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Prelude Therapeutics are expected to grow in the coming year, from ($1.82) to ($1.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Prelude Therapeutics is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Prelude Therapeutics is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Prelude Therapeutics has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.85% of the float of Prelude Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Prelude Therapeutics has a short interest ratio ("days to cover") of 8.6.

Change versus previous month

Short interest in Prelude Therapeutics has recently increased by 18.07%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Prelude Therapeutics does not currently pay a dividend.

Dividend Growth

Prelude Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.85% of the float of Prelude Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Prelude Therapeutics has a short interest ratio ("days to cover") of 8.6.

Change versus previous month

Short interest in Prelude Therapeutics has recently increased by 18.07%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: N/A

News Sentiment

Prelude Therapeutics has a news sentiment score of 1.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Prelude Therapeutics this week, compared to 1 article on an average week.

Search Interest

3 people have searched for PRLD on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Prelude Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Prelude Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

62.80% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.72% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PRLD Stock Analysis - Frequently Asked Questions

How have PRLD shares performed this year?

Prelude Therapeutics' stock was trading at $4.27 at the beginning of 2024. Since then, PRLD stock has decreased by 77.5% and is now trading at $0.9617.
View the best growth stocks for 2024 here.

How were Prelude Therapeutics' earnings last quarter?

Prelude Therapeutics Incorporated (NASDAQ:PRLD) issued its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.05. The business earned $3 million during the quarter.

When did Prelude Therapeutics IPO?

Prelude Therapeutics (PRLD) raised $149 million in an initial public offering on Friday, September 25th 2020. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities acted as the underwriters for the IPO.

Who are Prelude Therapeutics' major shareholders?

Top institutional shareholders of Prelude Therapeutics include Massachusetts Financial Services Co. MA (1.00%), Geode Capital Management LLC (0.71%), State Street Corp (0.52%) and Jacobs Levy Equity Management Inc. (0.32%). Insiders that own company stock include Orbimed Advisors Llc, Krishna Vaddi, Laurent Chardonnet and Andrew Combs.
View institutional ownership trends.

How do I buy shares of Prelude Therapeutics?

Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Prelude Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Prelude Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/20/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PRLD
• CUSIP: N/A
• CIK: 1678660
• Web: www.preludetx.com
• Phone: 302-467-1280
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.75
• High Stock Price Target: $7.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +393.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-121,830,000.00
• Net Margins: N/A
• Pretax Margin: -4,383.90%
• Return on Equity: -66.89%
• Return on Assets: -55.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.04
• Quick Ratio: 7.04

Sales & Book Value

• Annual Sales: $3 million
• Price / Sales: 17.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.32 per share
• Price / Book: 0.22

Miscellaneous

• Outstanding Shares: 55,035,000
• Free Float: 20,473,000
• Market Cap: $52.93 million
• Optionable: Optionable
• Beta: 1.56